Investing

Altimmune : ALT

ALT

Stock Data

$5.28

$0.01 (0.19%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Altimmune Inc is a biopharmaceutical company based in Gaithersburg, Maryland, focusing on innovative treatments for obesity and liver diseases. Its leading product, pemvidutide, is a promising obesity and non-alcoholic steatohepatitis treatment currently in Phase 2 trials. Additionally, Altimmune is developing HepTcell, aimed at treating chronic hepatitis B virus infections, also in Phase 2 trials. Founded in 1997 and originally named Vaxin Inc., the company rebranded to Altimmune Inc in 2015, continuing its mission to address critical unmet medical needs.

All Altimmune Articles

13 Articles

Ian Cooper | Oct 31, 2025 at 10:18 AM EDT

3 Explosive Stocks With High Short Interest

Short interest is always a sign of how bearish investors may be on a stock. But it can also serve…

Ian Cooper | Sep 12, 2024 at 11:50 AM EDT

Five Top Obesity Stocks to Buy and Hold Long Term

Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX), for example.…

Chris Lange | Dec 1, 2022 at 11:40 AM EST

With a Fed Rate Hike Coming, Analysts Upgrade or Downgrade Sirius XM, Tencent Music and More

Thursday’s additional top analyst upgrades and downgrades were on Ally Financial, Altimmune, Capital One Financial, GoodRx, Leslie’s, PagSeguro Digital, Regions…

Chris Lange | Dec 29, 2021 at 11:45 AM EST

Wednesday Afternoon’s Analyst Upgrades and Downgrades: Inovio Pharmaceuticals, McDonald’s, VBI Vaccines, Wingstop and More

Wednesday afternoon's top analyst upgrades and downgrades included Inovio Pharmaceuticals, McDonald’s, Orchard Therapeutics, VBI Vaccines and Wingstop.

Chris Lange | Jul 12, 2021 at 8:05 AM EDT

Jim Cramer’s Game Plan for This Week and the Start of Earnings Season

24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.

Lee Jackson | Jun 2, 2021 at 8:52 AM EDT

Wednesday’s Top Analyst Upgrades and Downgrades: Alphabet, Canopy Growth, Cinemark, Facebook, IMAX, Microsoft, Salesforce and More

Wednesday's top analyst upgrades and downgrades included Alphabet, Canopy Growth, Cinemark, Dick's Sporting Goods, Facebook, IMAX, Microsoft, Salesforce.com and SBA…

Chris Lange | Mar 15, 2021 at 9:57 AM EDT

Intranasal COVID-19 Vaccine Shows Very Promising Preclinical Results

Altimmune has announced additional preclinical data in regards to its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.

Lee Jackson | Feb 11, 2021 at 8:56 AM EST

Top Analyst Upgrades and Downgrades: Allstate, Bed Bath & Beyond, Simon Property, Spirit Airlines, Twitter, Under Armour and More

Thursday's top analyst upgrades and downgrades included Allstate, Bed Bath & Beyond, Simon Property, Spirit Airlines, Twitter and Under Armour.

Chris Lange | Dec 24, 2020 at 9:40 AM EST

How Big Is This Setback to Altimmune’s COVID-19 Vaccine Candidate?

Altimmune shares dropped on Thursday after the company announced that it had received an update from the FDA regarding its…

Chris Lange | Nov 10, 2020 at 12:18 PM EST

Altimmune Takes Next Step With Its COVID-19 Intranasal Vaccine

Altimmune made a step forward on Tuesday with its vaccine candidate for COVID-19. Specifically, the firm entered into a manufacturing…

Chris Lange | Jun 29, 2020 at 11:34 AM EDT

What This Capital Injection Means for Altimmune

Altimmune made some progress with its COVID-19 treatment on Monday after it announced some new funding for its trials.

Chris Lange | Mar 9, 2020 at 10:34 AM EDT

How Coronavirus Stocks Are Handling Monday’s Market Meltdown

24/7 Wall St. has tracked some stocks that either are defensive in general or are defying Monday's big drop because…

Chris Lange | Mar 19, 2019 at 9:55 AM EDT

What’s Next for Altimmune’s Influenza Vaccine

Altimmune shares surged on Tuesday following results from its midstage study of a intranasal influenza vaccine candidate.